Rybrevant
Janssen's Rybrevant, Chemo Regimen Nets FDA Approval in EGFR-Mutated NSCLC
The agency reviewed data from the MARIPOSA-2 trial and approved the regimen for patients with common EGFR mutations who are progressing on EGFR inhibitors.
J&J's Rybrevant, Lazcluze Land First-Line FDA Approval for Treating EGFR-Mutant NSCLC
The combination treatment is approved for patients whose lung tumors harbor EGFR exon 19 deletions or exon 21 L858R substitution mutations.
Johnson & Johnson Oncology Unit Revenues Jump 16 Percent in Q2
J&J reported a nearly 60 percent growth in sales of its top-selling precision oncology drug, the CAR T-cell therapy Carvykti, in Q2 2024 compared a year ago.
FDA Approves Janssen's Rybrevant, Chemo in Frontline NSCLC With EGFR Exon 20 Insertions
The agency also converted Rybrevant's accelerated approval to a full approval in previously treated NSCLC harboring these mutations.
J&J Seeking Frontline Rybrevant-Lazertinib FDA Approval in EGFR-Mutated NSCLC
The application contains data from the Phase III MARIPOSA trial in which the dual anti-EGFR regimen improved outcomes versus AstraZeneca's Tagrisso.